Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (Monitor-GCSF)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Sandoz.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Sandoz Identifier:
First received: August 30, 2011
Last updated: October 24, 2011
Last verified: October 2011

This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for febrile neutropenia (FN) who are receiving filgrastim biosimilar for primary or secondary FN prophylaxis to better describe the patient population at risk for FN, to describe prophylaxis patterns involving filgrastim biosimilar, and to evaluate hematology levels and variability in hematological outcomes, impact on chemotherapy and surgery, and mortality. Additionally the study aims to identify patient cohorts who are vulnerable to poor response to FN prophylaxis and break-through episodes of FN, understand the differences between prophylaxis responders and non-responders, and describe the degree to which therapy and prophylaxis of FN is in congruence with guideline recommendations.

Febrile Neutropenia
Breast Cancer
Ovarian Cancer
Lung Cancer
Prostate Cancer
Multiple Myeloma
Bladder Cancer
B-cell Lymphoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Absolute neutrophil count (ANC) [ Time Frame: 6 months, 6 cycles of chemotharapy ] [ Designated as safety issue: No ]
    Describe intraindividual changes in ANC.

Secondary Outcome Measures:
  • Cohort identification and differentiation [ Time Frame: 6 months, 6 cycles of chemotherapy ] [ Designated as safety issue: No ]
    Patient profiles based on medical history, concomitant comorbid conditions and current clinical status.

  • Nonresponder analyses [ Time Frame: 6 months, 6 cycles of chemotherapy ] [ Designated as safety issue: Yes ]

    Patient- and center-level variables between patients who had:

    • chemotherapy dose delays or reductions,
    • surgery delays or cancellations, and
    • radiotherapy delays, dose reductions or cancellations vs no such events and
    • patients who died vs. survived during the course of prophylaxis with filgrastim biosimilar in all patients and those with break-through FN episodes.

Estimated Enrollment: 1500
Study Start Date: February 2010
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Only 1 group
Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for febrile neutropenia.


Inclusion Criteria:

  • Male or female adults (age > / = 18 years)
  • Diagnosed with one of the following types and stages of tumors: stage III or IV breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large B-cell lymphoma; multiple myeloma.
  • Planned to receive primary prophylaxis with ZARZIO® at the first cycle of chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis with ZARZIO® irrespective of chemotherapy cycle.
  • Treated with commercially available ZARZIO® per physician's best clinical judgment and per current European ZARZIO® label.
  • Female patients must be either post-menopausal for one year or surgically sterile or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Oral contraceptive use is allowed.
  • Informed written consent to participate in the study by patients or their legal guardian.

Exclusion Criteria:

  • Patients with myeloid malignancies, with the exception of multiple myeloma.
  • Sensitivity to ZARZIO® or any other CSF.
  • Hypersensitivity to E. coli-derived proteins.
  • Radiotherapy to ≥ 20% of total body bone.
  • Infection within two weeks of starting current line of chemotherapy.
  • Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.
  • Patients with willfully negligent nonadherence to their cancer treatment.
  • Use of any investigational agent in the 30 days prior to enrollment.
  • Women of childbearing potential not using the contraception method(s) described above.
  • Women who are breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01459653

Contact: Matthew Turner +49 8024 476 ext 2272
Contact: Michael Muenzberg, MD +49 8024 476 ext 2253

Czech Republic
Nemocnice Znojmo Recruiting
Znojmo, Czech Republic, 66902
Contact: Karol Krizan, Dr.    +420515215123   
Principal Investigator: Karol Krizan, Dr.         
Hôpital Européen Georges Pompidou - Service Oncologie Médicale Recruiting
Paris, France, 75908
Contact: Florian Scotte, Dr.    +33156093473   
Principal Investigator: Florian Scotte, Dr         
Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie Recruiting
Hamburg, Germany, 20246
Contact: Carsten Bokemeyer, Prof.    +4940741052960   
Principal Investigator: Carsten Bokemeyer, Prof. Dr.         
Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino" Recruiting
Torino, Italy, 10126
Contact: Mario Boccadoro, Prof.    +390116336107   
Principal Investigator: Mario Boccadoro, Prof. Dr.         
SPSK1 Klinika Hematologii Recruiting
Lublin, Poland, 20-081
Contact: Anna Dmoszynska, Prof.    +48815345468   
Principal Investigator: Anna Dmoszynska, Prof. Dr.         
Centrul de Diagnostic si Tratament Euromedic Fundeni Recruiting
Bucuresti, Romania, 022328
Contact: Dana Stanculeanu, Dr.    +40744327992   
Principal Investigator: Dana Stanculeanu, Dr.         
Hospital Clinic i Provincial de Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Pere Gascón Vilaplana    +34932275400   
Principal Investigator: Pere Gascón Vilaplana         
IMO Clinique de Genolier Recruiting
Genolier, Switzerland, 1272
Contact: Matti Aapro, Dr.    +41223669134   
Principal Investigator: Matti Aapro, Dr.         
United Kingdom
The Rotherham NHS Foundation Trust - Dept. of Haematology Recruiting
Rotherham, United Kingdom, S60 2UD
Contact: Helen Barker, Dr.    +441709304720   
Principal Investigator: Helen Barker, Dr.         
Sponsors and Collaborators
Study Director: Matthew Turner, PhD Sandoz
  More Information

No publications provided

Responsible Party: Sandoz Identifier: NCT01459653     History of Changes
Other Study ID Numbers: Monitor-GCSF, EP-502
Study First Received: August 30, 2011
Last Updated: October 24, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Romania: National Medicines Agency
Czech Republic: State Institute for Drug Control

Keywords provided by Sandoz:
Febrile neutropenia
primary prophylaxis
secondary prophylaxis
granulocyte colony stimulating factor
observational study
noninterventional study

Additional relevant MeSH terms:
Neoplasms, Plasma Cell
Prostatic Neoplasms
Urinary Bladder Neoplasms
Ovarian Neoplasms
Breast Neoplasms
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Urologic Neoplasms
Endocrine Gland Neoplasms
Genital Neoplasms, Female
Multiple Myeloma
Lymphoma, B-Cell
Febrile Neutropenia
Chemotherapy-Induced Febrile Neutropenia
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases processed this record on September 22, 2014